BIO-TECHNE Corp(TECH)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

BIO-TECHNE Corp (TECH) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TECH at 58.9/100 on a 32-signal composite quality model, placing it at rank #966 of 2,961 stocks — the top half of the AI-ranked universe. TECH scores in the top quartile across profitability (79.0), earnings quality (77.8), balance sheet strength (77.1). Areas of concern include revenue growth (32.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 30.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), BIO-TECHNE Corp reports quarterly revenue of $321.2M, net income of $54.6M, free cash flow of $86.9M. Top institutional holders of TECH by reported 13-F value include BlackRock, FMR, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. TECH trades on the Nasdaq exchange and files with the SEC under CIK 842023. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TECH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BIO-TECHNE Corp directly from SEC EDGAR.